Submit Manuscript

E-Pub Full Text Articles

Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Author(s): Andrew Kyle Henderson Robertson, Caterina Fortunata Ramogida, Paul Schaffer and Valery Radchenko*
Pages: 1-17 (17)
Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies

Author(s): Joseph G. Jurcic*
Pages: 1-8 (8)
In vivo Evaluation of [225Ac]Ac-DOTAZOL for α-Therapy of Bone Metastases

Author(s): Nina Pfannkuchen, Nicole Bausbacher, Stefanie Pektor, Matthias Miederer and Frank Rosch*
Pages: 1-8 (8)
Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides

Author(s): George Sgouros*, Robert Hobbs and Anders Josefsson
Pages: 1-6 (6)
An Overview of Targeted Alpha Therapy with ²²⁵Actinium and ²¹³Bismuth

Author(s): Alfred Morgenstern*, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki and Frank Bruchertseifer
Pages: 1-9 (9)
NorthStar Perspectives for Actinium-225 Production at Commercial Scale

Author(s): James T. Harvey*
Pages: 1-12 (12)
The Production of Ac-225

Author(s): Jonathan W Engle*
Pages: 1-7 (7)
In vivo Evaluation of Free and Chelated Accelerator-produced Actinium- 225 - Radiation Dosimetry and Toxicity Results

Author(s): Zewei Jiang, Ekaterina Revskaya, Darrell R. Fisher and Ekaterina Dadachova*
Pages: 1-8 (8)